Personalis, Inc. (NASDAQ: PSNL) reported Q4 EPS of ($0.54), $0.04 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $19.7 million versus the consensus estimate of $19.75 million.

GUIDANCE:

Personalis, Inc. sees Q1 2024 revenue of $18-19 million, versus the consensus of $19.1 million.

Revenue from pharma tests, enterprise sales, and other customers to be in the range of $16.0 to $17.0 million
Revenue from population sequencing of approximately $2.0 million

Personalis expects the following for the full year of 2024:

Total company revenue in the range of $73.0 to $75.0 million, versus the consensus of $75.007 million
Revenue from pharma tests, enterprise sales, and all other customers in the range of $65.0 to $67.0 million
Revenue from population sequencing of approximately $8.0 million
Net loss of approximately $80.0 million, down from $108.3 million in 2023 due to realization of savings from the reduction in headcount, partially offset by investments in clinical evidence generation and costs for non-reimbursed clinical tests; the net loss estimate does not include any income or expense from the outstanding warrants issued to Tempus
Cash usage of approximately $62.0 million, inclusive of approximately $3.0 million for employee severance payments from the headcount reductions in the fourth quarter of 2023

For earnings history and earnings-related data on Personalis, Inc. (PSNL) click here.